Clinical trials: Retinal Vein Occlusions
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Branch Retinal Vein Occlusion, Macular Edema
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).
- Trial name
- BRAVE (NCT03108352)
- Testing
- Conbercept ophthalmic injection
- Where
- 31 sites in China
- Volunteers
- 255 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Macular Edema, Central Retinal Vein Occlusion
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study.
- Trial name
- CRAVE (NCT03223714)
- Testing
- Conbercept Ophthalmic Injection
- Where
- 27 sites in China
- Volunteers
- 242 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO).
- Trial name
- NCT03739593
- Testing
- AR-1105-CF1, AR-1105-CF2
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company
Retinal Vein Occlusion, Macula Edema
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
- Trial name
- NCT03093701
- Testing
- TLC399 (ProDex)
- Where
- 20 sites in United States
- Volunteers
- 31 people
- Sponsor
- Taiwan Liposome Company
Central Retinal Vein Occlusion
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years.
- Trial name
- SCORE2 (NCT01969708)
- Testing
- aflibercept, bevacizumab
- Where
- 72 sites in United States
- Volunteers
- 362 people
- Sponsor
- The Emmes Company, LLC
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
- Trial name
- SAPPHIRE (NCT02980874)
- Testing
- suprachoroidal CLS-TA, IVT aflibercept
- Where
- 110 sites in United States, Australia and 14 more
- Volunteers
- 460 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Edema, Macular Degeneration
Study Evaluating Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04428242
- Testing
- RHMS-RTM, SD-OCT
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Macular Edema, Macular Degeneration
Evaluation of the Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04499703
- Testing
- RHMS-RTM, SD-OCT
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given…
- Trial name
- TANZANITE (NCT02303184)
- Testing
- 4 mg CLS-TA, IVT aflibercept
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Clearside Biomedical, Inc.
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Retinal Vein Occlusion, Diabetic Macular Edema
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or…
- Trial name
- Molokini (NCT02245516)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kala Pharmaceuticals, Inc.